Therefore, our results indicate that dipyridamole alone may sufficiently reduce ER − HER2 + tumour growth in vivo and support EDI3 as a potential therapeutic target in tumours of this molecular subtype that are resistant to HER2-targeting therapy. Here, ERBB2 is linked to neoplasm.